Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

WAVE Life Sciences Ltd

Start price
Target price
Perf. (%)
€6.40
04.11.20
-
-9.38%
07.11.20

Could be very worthwhile Investment >20% year
buy
BioLine RX Ltd ADR

Start price
Target price
Perf. (%)
€2.46
03.11.20
€3.50
04.11.21
-4.88%
05.11.21

Could be worthwhile Investment >10% per year
buy
DBV Technologies S.A.

Start price
Target price
Perf. (%)
€3.45
03.11.20
-
04.11.21
136.51%
15.01.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
buy
DBV Technologies S.A.

Start price
Target price
Perf. (%)
€3.53
03.11.20
€10.50
04.11.21
51.47%
05.11.21

Could be worthwhile Investment >10% per year
buy
Sorrento Therapeutics Inc.

Start price
Target price
Perf. (%)
€6.15
02.11.20
€13.00
04.11.21
-4.96%
05.11.21

Could be very worthwhile Investment >20% year
Very Future proof/growth oriented business model
Top 10 in its market
Leading role in innovation
Sorrento Therapeutics Inc.

Start price
Target price
Perf. (%)
€6.20
02.11.20
€5.00
02.11.20
-0.74%
02.11.20

Could be very worthwhile Investment >20% year
Very Future proof/growth oriented business model
Top 10 in its market
Leading role in innovation
Bellicum Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€3.08
02.11.20
-
04.11.21
-25.32%
07.11.20

Probably not worthwhile Investment
buy
Aphria Inc.

Start price
Target price
Perf. (%)
€3.92
31.10.20
-
04.11.21
20.56%
09.11.20

buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€16.60
31.10.20
-
04.11.21
24.82%
09.11.20

buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€49.75
31.10.20
-
04.11.21
0.53%
09.11.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
BioLine RX Ltd ADR

Start price
Target price
Perf. (%)
€2.36
30.10.20
€2.00
31.10.20
-25.00%
31.10.20

Risky Investment
WAVE Life Sciences Ltd

Start price
Target price
Perf. (%)
€6.45
29.10.20
-
04.11.21
-0.78%
04.11.20

Could be very worthwhile Investment >20% year
Cocrystal Pharma Inc.

Start price
Target price
Perf. (%)
€8.64
28.10.20
-
04.11.21
31.94%
15.07.21

Could be very worthwhile Investment >20% year
Horizon Pharma plc

Start price
Target price
Perf. (%)
€65.91
28.10.20
-
04.11.21
-7.22%
13.11.20

Could be very worthwhile Investment >20% year
buy
Kala Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€267.50
27.10.20
€300.00
31.10.20
8.41%
31.10.20

Could be worthwhile Investment >10% per year
Inovio Pharma

Start price
Target price
Perf. (%)
€8.90
27.10.20
-
04.11.21
-24.99%
15.07.21

Risky Investment
WAVE Life Sciences Ltd

Start price
Target price
Perf. (%)
€6.50
27.10.20
-
29.10.20
-0.77%
29.10.20

Could be very worthwhile Investment >20% year
Horizon Pharma plc

Start price
Target price
Perf. (%)
€65.45
26.10.20
-
28.10.20
0.70%
28.10.20

Could be very worthwhile Investment >20% year
WAVE Life Sciences Ltd

Start price
Target price
Perf. (%)
€6.60
26.10.20
-
27.10.20
-1.52%
27.10.20

Could be very worthwhile Investment >20% year
Inovio Pharma

Start price
Target price
Perf. (%)
€8.90
26.10.20
-
27.10.20
0.00%
27.10.20

Risky Investment
Inovio Pharma

Start price
Target price
Perf. (%)
€8.95
26.10.20
-
26.10.20
-0.56%
26.10.20

Risky Investment
Inovio Pharma

Start price
Target price
Perf. (%)
€9.25
26.10.20
-
26.10.20
-3.24%
26.10.20

Risky Investment
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€51.03
24.10.20
€58.00
04.11.21
-0.20%
11.11.20

Medium risks for its business
Risky Investment
CytoDyn Inc_INT

Start price
Target price
Perf. (%)
€2.10
23.10.20
€1.00
04.11.21
7.62%
04.11.20

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Significant cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€42.35
23.10.20
€54.00
04.11.21
17.72%
05.11.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group